KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Assets Average (2020 - 2025)

Historic Assets Average for Royalty Pharma (RPRX) over the last 6 years, with Q4 2025 value amounting to $19.5 billion.

  • Royalty Pharma's Assets Average rose 745.38% to $19.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $19.5 billion, marking a year-over-year increase of 745.38%. This contributed to the annual value of $18.9 billion for FY2025, which is 935.98% up from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Assets Average is $19.5 billion, which was up 745.38% from $18.8 billion recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Assets Average ranged from a high of $19.5 billion in Q4 2025 and a low of $16.0 billion during Q1 2021
  • Moreover, its 5-year median value for Assets Average was $17.3 billion (2022), whereas its average is $17.3 billion.
  • In the last 5 years, Royalty Pharma's Assets Average tumbled by 687.89% in 2023 and then skyrocketed by 1249.35% in 2024.
  • Over the past 5 years, Royalty Pharma's Assets Average (Quarter) stood at $17.6 billion in 2021, then fell by 2.16% to $17.2 billion in 2022, then fell by 6.52% to $16.1 billion in 2023, then grew by 12.49% to $18.1 billion in 2024, then increased by 7.45% to $19.5 billion in 2025.
  • Its last three reported values are $19.5 billion in Q4 2025, $18.8 billion for Q3 2025, and $18.0 billion during Q2 2025.